Vectans Pharma - Transmucosal technology, targeted efficacy, improved compliance

ABOUT VECTANS PHARMA

Vectans Pharma is a European-based pharmaceutical company with a primary focus to target unmet needs in patients with oral pathologies through the acquisition and worldwide commercial development of innovative targeted therapeutics.

Created in 2015 by Jean et Jérôme Théron, Vectans Pharma is strategically and financially backed by top-notch private investors from the healthcare industry.

Our current portfolio includes Sitavig^® and Loramyc^®, 2 products approved by FDA (Food and Drug Administration) and several authorities in Europe and 1 proprietary innovative galenic technology : Lauriad^®. Loramyc^® is available in the US, Italy and France. Sitavig^® is available in the US and has been launched in September 2018 in France. Vectans Pharma is the Marketing Authorization Holder (MAH) in the majority of european markets. Vectans Pharma concluded international licensing agreements in Europe, the US, Latin America and Asia, allowing distribution of Sitavig^® and Loramyc^®.

International roll-out will continue in Asia and Europe.

Vectans Pharma is committed to rapidly become a worldwide pharmaceutical company leader in oral pathologies supporting patients with unmet needs.

NEWS

Meeting on ORAVI® /LORAMYC® with Sosei Heptares and FujiFilm Pharma

Vectans Pharma participated to the Commemorative Lecture for new release of ORAVI®/LORAMYC® Mucoadhesive Tablet 50mg, a meeting organized by Sosei Heptares and FujiFilm Pharma.

Jonathan Cohen appointed as Regulatory Affairs Manager

“ It is with great pleasure that I am strengthening the Regulatory Affairs Department, to lead the various projects of Vectans Pharma both in France and internationally. “

More news